Caplin Point Laboratories Limited (CAPLIPOINT) AI Stock Analysis

• Market Cap: ₹159.32B
• Dividend Yield: 0.25%
• Average Volume (3M): 6.12K
• Price to Earnings (P/E): 28.2
• Beta (1Y): 1.14
• Revenue Growth: 13.14%
• EPS Growth: 18.21%
• Country: IN
• Employees: 3,406
• Sector: Healthcare
• Sector Strength: 41
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 20.10
• Shares Outstanding: 76,011,696
• 10 Day Avg. Volume: 8,949
• 30 Day Avg. Volume: 6,117
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹2,315.00
• Price Target Upside: 7.17% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 75 Outperform
• Price Target: ₹2,315.00 ▲(7.17% Upside)

Caplin Point Laboratories' strong financial performance is the most significant factor driving its stock score, supported by robust revenue growth and solid profitability. Technical analysis indicates neutral momentum, while valuation suggests moderate pricing. The absence of earnings call data and corporate events limits additional insights.

Caplin Point Laboratories Limited Business Overview & Revenue Model

Company Description

Caplin Point Laboratories Limited is a pharmaceutical company based in India that specializes in the development, manufacturing, and distribution of a wide range of pharmaceutical products. The company operates in the sectors of generic pharmaceuticals and over-the-counter (OTC) medications. Its core products include formulations in various dosage forms such as tablets, capsules, ointments, and injectables, catering primarily to emerging markets.

How the Company Makes Money

Caplin Point Laboratories Limited generates revenue through the sale of its pharmaceutical products, primarily in emerging markets across Latin America, Africa, and Southeast Asia. The company's key revenue streams include the manufacture and distribution of generic medications and OTC products. Caplin Point focuses on high-growth regions with demand for affordable medications, capitalizing on its strong distribution network and local partnerships to maximize market penetration. The company benefits from cost-effective production capabilities and a diverse product portfolio, which contribute to its competitive pricing strategy and profitability.

Caplin Point Laboratories Limited Financial Statement Overview

Summary

Caplin Point Laboratories exhibits strong financial health with robust revenue growth, efficient cost management, and solid profitability across income, balance sheet, and cash flow metrics. The low debt-to-equity ratio and strong cash flow generation position the company well for future growth.

Income Statement

Caplin Point Laboratories has demonstrated strong revenue growth, with a significant increase in total revenue over the past five years. The gross profit margin is robust, indicating efficient cost management. Additionally, the EBIT and EBITDA margins highlight strong operational performance, while the net profit margin reflects effective bottom-line management.

Balance Sheet

The company's balance sheet is solid, featuring a low debt-to-equity ratio which suggests prudent financial leverage. The equity ratio is high, showcasing a strong equity position relative to total assets. Return on equity has shown positive trends, reflecting good profitability on shareholders' investments.

Cash Flow

Caplin Point Laboratories has a healthy cash flow, with consistent growth in free cash flow. The operating cash flow to net income ratio indicates strong cash generation relative to net income, supporting business sustainability. The free cash flow to net income ratio is solid, ensuring ample cash availability for reinvestment or debt reduction.

Breakdown	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	19.37B	16.77B	14.67B	12.63B	10.48B
Gross Profit	11.67B	9.21B	8.04B	7.03B	5.73B
EBITDA	6.47B	6.18B	4.97B	4.33B	3.52B
Net Income	5.36B	4.57B	3.76B	3.00B	2.42B
Balance Sheet
Total Assets	32.09B	26.98B	21.91B	17.36B	13.64B
Cash, Cash Equivalents and Short-Term Investments	9.03B	7.88B	7.25B	6.27B	4.67B
Total Debt	50.20M	19.70M	52.00M	21.30M	183.92M
Total Liabilities	3.22B	3.51B	2.84B	2.26B	1.60B
Stockholders Equity	28.50B	23.16B	18.80B	14.84B	11.86B
Cash Flow
Free Cash Flow	2.41B	1.73B	779.00M	2.46B	1.95B
Operating Cash Flow	4.32B	3.18B	2.72B	3.37B	2.66B
Investing Cash Flow	-3.35B	-3.20B	-2.18B	-2.71B	-53.60M
Financing Cash Flow	-383.20M	-380.70M	-281.70M	-407.10M	-239.78M

Caplin Point Laboratories Limited Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2160.20
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:CAPLIPOINT, the sentiment is Positive. The current price of 2160.2 is above the 20-day moving average (MA) of 2065.60, above the 50-day MA of 2064.76, and above the 200-day MA of 2078.72, indicating a bullish trend. The MACD of 0.56 indicates Negative momentum. The RSI at 53.91 is Neutral, neither overbought nor oversold. The STOCH value of 79.63 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:CAPLIPOINT.

Caplin Point Laboratories Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CAPLIPOINT	75 Outperform	₹159.32B	28.19		0.25%	13.14%	18.21%
NATCOPHARM	74 Outperform	₹159.02B	9.37		0.68%	10.77%	36.14%
GRANULES	65 Neutral	₹110.46B	23.02		0.33%	-0.55%	23.68%
NEULANDLAB	65 Neutral	₹166.81B	94.70		0.09%	-18.66%	-47.59%
APLLTD	59 Neutral	₹186.09B	30.86		1.16%	8.20%	-4.26%
Sector *	51 Neutral	$7.42B	-0.36	-40.86%	2.27%	22.89%	-2.16%

Caplin Point Laboratories Limited Corporate Events

Caplin Point Laboratories Sets Record Date for Dividend Ahead of AGM

Caplin Point Laboratories Limited has announced the record date for its dividend payment as September 12, 2025, in accordance with the SEBI Listing Regulations. The company will hold its 34th Annual General Meeting on September 22, 2025, where the final dividend for the financial year 2024-25 will be discussed and potentially declared. This announcement is significant for shareholders as it outlines the timeline for dividend payments and the upcoming AGM, which are crucial for understanding the company’s financial health and shareholder returns.